cGAS-STING pathway in cancer biotherapy
Abstract The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. T...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2020-09-01
|
| Series: | Molecular Cancer |
| Subjects: | |
| Online Access: | http://link.springer.com/article/10.1186/s12943-020-01247-w |
| _version_ | 1828526553846251520 |
|---|---|
| author | Yang Wang Jingwen Luo Aqu Alu Xuejiao Han Yuquan Wei Xiawei Wei |
| author_facet | Yang Wang Jingwen Luo Aqu Alu Xuejiao Han Yuquan Wei Xiawei Wei |
| author_sort | Yang Wang |
| collection | DOAJ |
| description | Abstract The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The understanding of both intracellular cascade reaction and the changes of molecular components gains insight into type I IFNs and adaptive immunity. Based on the immunological study, the STING-cGAS pathway is coupled to cancer biotherapy. The most challenging problem is the limited therapeutic effect. Therefore, people view 5, 6-dimethylxanthenone-4-acetic acid, cyclic dinucleotides and various derivative as cGAS-STING pathway agonists. Even so, these agonists have flaws in decreasing biotherapeutic efficacy. Subsequently, we exploited agonist delivery systems (nanocarriers, microparticles and hydrogels). The article will discuss the activation of the cGAS-STING pathway and underlying mechanisms, with an introduction of cGAS-STING agonists, related clinical trials and agonist delivery systems. |
| first_indexed | 2024-12-11T21:26:26Z |
| format | Article |
| id | doaj.art-1a3a5f9c1e634b2399290780c6f964c1 |
| institution | Directory Open Access Journal |
| issn | 1476-4598 |
| language | English |
| last_indexed | 2024-12-11T21:26:26Z |
| publishDate | 2020-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Molecular Cancer |
| spelling | doaj.art-1a3a5f9c1e634b2399290780c6f964c12022-12-22T00:50:19ZengBMCMolecular Cancer1476-45982020-09-0119111610.1186/s12943-020-01247-wcGAS-STING pathway in cancer biotherapyYang Wang0Jingwen Luo1Aqu Alu2Xuejiao Han3Yuquan Wei4Xiawei Wei5Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityLaboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy, National Clinical Research Center for Geriatrics, West China Hospital, Sichuan UniversityAbstract The activation of the cGAS-STING pathway has tremendous potential to improve anti-tumor immunity by generating type I interferons. In recent decades, we have witnessed that producing dsDNA upon various stimuli is an initiative factor, triggering the cGAS-SING pathway for a defensive host. The understanding of both intracellular cascade reaction and the changes of molecular components gains insight into type I IFNs and adaptive immunity. Based on the immunological study, the STING-cGAS pathway is coupled to cancer biotherapy. The most challenging problem is the limited therapeutic effect. Therefore, people view 5, 6-dimethylxanthenone-4-acetic acid, cyclic dinucleotides and various derivative as cGAS-STING pathway agonists. Even so, these agonists have flaws in decreasing biotherapeutic efficacy. Subsequently, we exploited agonist delivery systems (nanocarriers, microparticles and hydrogels). The article will discuss the activation of the cGAS-STING pathway and underlying mechanisms, with an introduction of cGAS-STING agonists, related clinical trials and agonist delivery systems.http://link.springer.com/article/10.1186/s12943-020-01247-wcGAS-STING pathwayCancer biotherapyInterferonCyclic dinucleotideAgonistDelivery system |
| spellingShingle | Yang Wang Jingwen Luo Aqu Alu Xuejiao Han Yuquan Wei Xiawei Wei cGAS-STING pathway in cancer biotherapy Molecular Cancer cGAS-STING pathway Cancer biotherapy Interferon Cyclic dinucleotide Agonist Delivery system |
| title | cGAS-STING pathway in cancer biotherapy |
| title_full | cGAS-STING pathway in cancer biotherapy |
| title_fullStr | cGAS-STING pathway in cancer biotherapy |
| title_full_unstemmed | cGAS-STING pathway in cancer biotherapy |
| title_short | cGAS-STING pathway in cancer biotherapy |
| title_sort | cgas sting pathway in cancer biotherapy |
| topic | cGAS-STING pathway Cancer biotherapy Interferon Cyclic dinucleotide Agonist Delivery system |
| url | http://link.springer.com/article/10.1186/s12943-020-01247-w |
| work_keys_str_mv | AT yangwang cgasstingpathwayincancerbiotherapy AT jingwenluo cgasstingpathwayincancerbiotherapy AT aqualu cgasstingpathwayincancerbiotherapy AT xuejiaohan cgasstingpathwayincancerbiotherapy AT yuquanwei cgasstingpathwayincancerbiotherapy AT xiaweiwei cgasstingpathwayincancerbiotherapy |